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Abstract
The central objective of the current study was to investigate the potential in vitro anti-proliferative effect of the parent ligand, 4-
methylcoumarin-6,7-dioxyacyeic acid (4-MecdoaH2), and its copper (II) complex, bis(phenanthroline4-methylcoumarin-6,7-dioxacetatocopper(II)
([Cu(4-Mecdoa)(phen)2]) using four human model cell lines. In addition, selected mechanistic studies were carried out using the most sensitive of
the four cell lines. Results obtained show that the complex could alter proliferation of both human neoplastic renal (A-498) and hepatic (HepG2)
cells. Furthermore, non-neoplastic hepatic (CHANG) cells appeared to be less sensitive. However, this effect was not duplicated with non-
neoplastic renal (HK-2) cells, a profile shared by cisplatin. The observed anti-proliferative effect appeared to be dose-and time-dependent, and
could be attributed to the complex, rather than any of the free components i.e. the 1,10-phenanthroline or coumarin ligand, or the simple metal salt.
Furthermore, the complex was shown to decrease DNA synthesis, but did not intercalate with it. Based on IC50 values, [Cu(4-Mecdoa)(phen)2]
was shown to be almost 12 times more potent than cisplatin. Moreover, there was no evidence that P-glycoprotein-mediated multi-drug resistance
was likely to decrease anti-proliferative activity. Cytological stains, analysis of genomic DNA, and biochemical assays [caspase-3 and -9 and
cleaved poly(ADP-ribose)-polymerase protein], showed that cell death could switch between apoptosis and necrosis, and this effect appeared to be
concentration-dependent. Additionally, flow cytometric analysis showed that the complex functioned through an alteration in cell cycle
progression. Taken together, [Cu(4-Mecdoa)(phen)2] has been shown to be a more potent anti-proliferative agent than either the ligand or cisplatin,
and is capable of altering key biochemical events leading to the execution of apoptotic and/or necrotic cell death, suggesting that it is worthy of
further investigation.
© 2007 Published by Elsevier B.V.
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1. Introduction
There have been a number of reports highlighting the use of
transition metal complexes as anti-cancer agents (Fricker,
1994). Probably the best known of these drugs is cisplatin
[cis-diamminedichloroplatinum(II)] which has been widely
used in the treatment of a variety of cancers, especially
testicular cancer, with a 70–90% cure rate. When combined
with other drugs, it has successfully been used to treat brain,
ovarian, bladder and breast cancer (Marzano et al., 2002). The
clinical success of cisplatin is limited by its significant side
effects, such as nausea, vomiting, severe nephrotoxicity, and
genotoxicity (Marzano et al., 2002). The use of cisplatin and
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related platinum complexes as anti-cancer agents has stimulated
a search for other active transition metal complexes which are as
or more effective, but with lesser side effects.
Coumarins comprise a very large class of compounds found
throughout the plant kingdom (Murray et al., 1982; Egan et al.,
1990). The bio-activity of coumarin and more complex related
derivatives appears to be based on the coumarin nucleus
(Kolodziej et al., 1997; Jimenez-Orozco et al., 1999; Finn et al.,
2001; Finn et al., 2004a). Biological effects observed include anti-
bacterial (Laurin et al., 1999), anti-thrombotic and vasodilatory
(Hoult and Paya, 1996), anti-mutagenic (Pillai et al., 1999),
lipoxygenase and cyclooxygenase inhibition (Kimura et al., 1985;
Hoffmanova et al., 1998), and scavenging of reactive oxygen
species, as well as anti-tumourigenic effects (Maucher et al.,
1993; Sharma et al., 1994; Egan et al., 1997; Hayes et al., 1998;
Finn et al., 2004a; Finn et al., 2004b). Since the late 1980's, a
number of in vivo studies have investigated the possible use of
coumarins in the treatment of renal cell carcinoma (Marshall et al.,
1986, 1994). All of these studies have demonstrated a significant
response rate following coumarin treatment alone or in
combination therapy. The in vitro effects of coumarins on the
growth of renal cell carcinoma-derived cell lines showed that
coumarin and 7-hydroxycoumarin were potent cytotoxic and
cytostatic agents (Marshall et al., 1994). Recent studies carried out
in our laboratory compared the anti-proliferative capability of a
series of natural and synthetic nitro and hydroxylated derivatives
of coumarin, including 6-nitro-7-hydroxycoumarin and 7,8-
dihydroxycoumarin, using both renal adenocarcinoma and
malignant melanoma cell lines. These compounds were shown
to be potent cytotoxic agents, capable of killing cancer cells by
modulation of key biochemical pathways such as mitogen-
activated protein kinases (Finn et al., 2004a; Finn et al., 2004b;
Finn et al., 2005a,b).
Interest in metal–coumarin complexes has arisen from the
search for novel lead compounds, along with the desire to
improve the pharmacological profile of established anti-
neoplastic agents. Kokotos et al. (1997) synthesised a number
of amino–coumarin–platinum(II) complexes and evaluated
their in vitro anti-proliferative activity using a colonic carcinoma
cell line (Caco-2). They screened a number of coumarins with an
amino group at position six or seven and methyl groups at
various positions around the coumarin nucleus. These research-
ers found that the most potent platinum–coumarin complex had
functional groups attached at position six. More recently,
Manalov et al. (2002) investigated the in vitro cytotoxicity of a
number of coumarin complexes with the late transition metal,
cerium, using both Burkitt lymphoma (P3HR1) and leukemic
(THP-1) cell lines. These researchers found that complexation
resulted in a 40% increase in cytotoxicity, compared to the
metal-free ligand. Additionally, Kostova et al. (2001) studied the
effects of coumarin complexed to zirconium. Here again it was
found that metal–coumarin complexes were more active on their
own.
1,10-phenanthroline and its substituted derivatives, both in
the metal-free state and as ligands co-ordinated to transition
metals, have been shown to disturb the functioning of a wide
variety of biological systems (Butler et al., 1969). Furthermore,
when metal-freeN,N'-chelating bases are found to be bioactive it
is usually assumed that the sequestering of trace metals in situ is
involved, and that the resulting metal complexes are the active
species (MacLeod, 1952; Dwyer et al., 1969). Previous work has
shown that the metal–phenanthroline complexes namely; [Cu
(phen)2(mal)] ×2H2O, [Mn(phen)2(mal)] ×2H2O, and [Ag2
(phen)3(mal)]×2H2O (malH2=malonic acid) could inhibit
growth of the fungal pathogen Candida albicans by around
95% at a concentration range of 1.25–5.0 μg/ml (McCann et al.,
2000; Coyle et al., 2003). Our research group has studied the
potential in vitro anti-proliferative effect of these three metal
complexes using human-derived cell lines. Deegan et al. (2007)
showed that all three of these complexes could decrease cell
proliferation. In comparative studies with cisplatin and based on
IC50 values, all three complexes were found to be significantly
more potent than cisplatin. In addition, of the three complexes
studied Cu(phen)2(mal)]×2H2O appeared to be the most
biologically active. Recently, Heffeter et al. (2006) showed
that a lanthanium complex of 1,10-phenanthroline, namely [tris
(1,10-phenanthroline)lanthanium(III)trithiocyanate] could in-
duce apoptosis in human-derived cell lines. They showed that
by 24 h, the complex (5 μM) caused condensation of chromatin,
along with nuclear fragmentation. In addition, they showed that
this effect was mediated through activation of caspase-3 and -7,
leading to cleavage of poly(ADP-ribose)polymerase (PARP).
Based on these findings, the authors suggested that mitochondria
were central in controlling this effect.
Other researchers have shown that [Cu(phen)2]
2+ was a
biologically active metal–phenanthroline complex (Samuni
et al., 1981; Wijker and Lafleur, 1999). This agent has been
shown to promote hydroxyl radical formation from molecular
oxygen by redox-cycling and could therefore be considered
suitable for stimulating the production of reactive oxygen
species. Transition metal cations such as Cu(II) and Fe(II) bind
to negatively-charged DNA and have been shown to play an
important role in the local formation of OH radicals (Samuni
et al., 1981; Wijker and Lafleur 1999). One of the consequences
of high copper levels in the body has been shown to be an
increase in the rate of radical formation leading to oxidative
damage, resulting in disruption of lipid bilayers due to oxidation
and cleavage of vulnerable unsaturated fatty acid residues of
phospholipids (Linder, 2001). Alterations in protein function
have also been shown to be promoted through oxidation of thiol
and possibly amino groups. In addition, researchers have
suggested that gene expression may be altered due to oxidation
of guanosine and adenosine residues in nucleic acids, along with
an alteration in transcription factor/growth factor activities
(Linder, 2001). Tsang et al. (1996) reported that incubation of a
human hepatic cell line (Hep-G2) with [Cu(phen)2]
2+ resulted in
internucleosomal DNA fragmentation. Zhou et al. (2002) also
reported G1-specific apoptosis in a liver carcinoma cell line (Bel-
7402), caused by [Cu(phen)2]
2+. Additionally, this complex was
shown to up-regulate the DNA-binding activity of p53, a
molecule know to be pivotal in the regulation of cell progression,
cell survival and apoptosis (Verhaegh et al., 1997).
Given the anti-cancer properties of metal-based derivatives
of both coumarin and 1,10-phenanthroline, we decided to
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determine whether a complex composed of each of these
component parts (Fig. 1) could decrease the in vitro proliferative
activity of human cancer cell lines. Therefore, the central
objective of this study was to use a number of in vitro-based
techniques to illustrate whether this agent could selectively
alter the proliferative of cancer cells, and in doing so elucidate
its molecular mechanism of action. In addition, comparative
studies were carried out in order to highlight the potential
benefits of this compound, relative to one of the best known and
most widely used metal-based anti-cancer drugs, cisplatin.
2. Materials and methods
2.1. Test compounds and reagents
Cisplatin, phenanthroline, Cu(ClO4)2, and dimethyl sulfox-
ide (DMSO) were purchased from Sigma-Aldrich, Ireland Ltd
and used as received. The preparation of the novel ligand 4-
MecdoaH and its Cu(II) complex, [Cu(4-Mecdoa)(phen)2] are
described in full in another publication (Creaven et al., in press).
Structure and purity were confirmed by thin layer chromatog-
raphy, infra red analysis, 1H-and 13C-NMR spectroscopy, along
with elemental analysis. The X-ray crystal structure of the
copper(II) complex showed a trigonal bipyramidal geometry
about the metal centre, with the copper atom bound to four
nitrogen atoms of the two chelating phen ligands and a single
oxygen from one of the carboxylate moieties of the Mecdoa2-
ligands.
The chemiluminescence substrate Luminol was purchased
from Pierce Laboratories (UK), while antibodies specific to
cleaved poly(ADP-ribose)polymerase (PARP) were purchased
from New England Biolabs, and the DNA fragmentation kit was
obtained from Oncogene, UK. Jsb-1, the antibody specific for
P-glycoprotein was purchased from Cappell, UK. All cell
culture reagents and media were purchased from Euroclone,
UK, unless otherwise stated.
2.2. Model cell lines
A-498 (human kidney adenocarcinoma), HK-2 (human
proximal tubular), CHANG (human hepatic), and Hep-G2
(human hepatocellular carcinoma) cells were purchased from
the American Type Culture Collection, Manassas, USA. A-498,
CHANG, and Hep-G2 cells were maintained in Eagle's
Minimum Essential Medium (EMEM) with Earle's Balanced
Salt Solution, containing 1.5 g/L sodium bicarbonate, 2 mM L-
glutamine, 0.1 mM non-essential amino acids, 1 mM sodium
pyruvate, 100 U/ml penicillin, 100 μg/ml streptomycin and 10%
(v/v) foetal bovine serum (Sigma). HK-2 cells were maintained
in Dulbecco's Modified Eagle's Medium/Nutrient Hams F12
(50:50, v/v), supplemented with 2 mM L-glutamine, ITS (5 μg/
ml bovine insulin, 5 μg/ml human transferrin, 5 ng/ml
selenium), 36 ng/ml hydrocortisone, 4 pg/ml 3,3′,5-tri-iodo-L-
thyronine, and 10 ng/ml epidermal growth factor. All cell lines
were grown at 37 °C in a humidified atmosphere with 5% CO2,
and were in the exponential phase of growth at the time of
inclusion in assays.
Chinese hamster ovary cells (CHO-K1 and CHRC5) were
kindly provided by Dr. V. Ling, Ontario, Canada. CHO-K1 cells
were maintained in F-12, containing 2 mM L-glutamine, 100 U/
ml penicillin, 100 μg/ml streptomycin and 10% (v/v) foetal
bovine serum. CHRC5 cells were maintained in EMEM, Alpha
modification (without ribonucleosides and deoxynucleosides),
containing 2 mM L-glutamine, 100 U/ml penicillin, 100 μg/ml
streptomycin, and 10% (v/v) foetal bovine serum. All cell lines
were grown at 37 °C in a humidified atmosphere and in the
presence of 5% CO2.
2.3. Assessment of anti-proliferative activity using MTT assay
4-MecdoaH2, [Cu(4-Mecdoa)(phen)2], phenanthroline, cis-
platin, and Cu(ClO4)2 were dissolved in DMSO, diluted in
culture media and used to treat model cells over a range of drug
concentrations for periods of 4, 24, and 96 h. The maximum
percentage of DMSO present in any well was 0.05% (v/v). Cells
were seeded in sterile 96-well flat-bottomed plates (Sarstedt) at
a density of 5×104 cells/ml and grown in 5% CO2 at 37 °C. A
miniaturised viability assay using 3-(4,5-dimethylthiazol-2-yl)-
Fig. 1. Structures of (A) 4-MecdoaH2 and (B) [Cu(4-Mecdoa)(phen)2] used in
this study.
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2,5-diphenyl-2H-tetrazolium bromide (MTT) was carried out
according to the method described by Mosmann (1983). In
metabolically active cells, MTT is reduced by the mitochondrial
enzyme succinate dehydrogenase to form insoluble purple
formazan crystals that are subsequently solubilised, and the
optical density (OD) measured spectrophotometrically and
consequently used to illustrate cell arrest. Drug-treated cells
were assayed by the addition of 20 μl of 5 mg/ml MTT in 0.1 M
phosphate buffer saline (PBS), pH 7.4. Following incubation for
4 h at 37 °C, the overlying medium was aspirated with a syringe
and 100 μl of DMSO was added to dissolve the formazan
crystals. Plates were agitated at high speed to ensure complete
dissolution of crystals and OD was measured at 550 nm using
an Anthos HT-II microtitreplate reader. Viability was expressed
as a percentage of solvent-treated control cells. This assay had
five replicates and each experiment was carried out on at least
three separate occasions. The IC50 was calculated and defined as
the drug concentration (μM) causing a 50% reduction in cellular
viability.
2.4. Confirmation of MDR-1 phenotype
The pleotrophic drug-resistant cell line (CHRC5) has
previously been shown to over-express the MDR-1 gene
product, P-glyocprotein-170, and to exhibit cross-resistance to
structurally dissimilar drugs, while the P-glycoprotein-negative
CHO-K1 fails to exhibit the MDR-1 phenotype (Hamilton et al.,
1985). To confirm these drug phenotypes, both CHRC5 and
CHO-K1 cells were assessed for chemosensitivity by contin-
uous exposure to a known anti-cancer drug, vinblastin. The
viability of CHRC5 and CHO-K1 cell lines was assessed in
parallel using a 96-well format with increasing concentration of
vinblastin (0–10 μM). Briefly, the cell density of both cell lines
was adjusted to 5×104 cells/ml, and 100 μl of cell suspension
was added per well to a 96-well plate (Falcon). Following
overnight incubation, a concentrated stock solution of each of
the test compounds prepared in DMSO was stored at −20 °C,
thawed directly prior to the assay, and the required dilutions
were prepared by serial dilution in complete culture medium.
The maximum concentration of DMSO present in all wells was
0.05% (v/v), a concentration which exhibited no effect on cell
morphology or growth. Viability was determined using the
MTT assay (Mosmann, 1983) as outlined in Section 2.3. The
relative degree of resistance for each cell line was determined by
comparison of the IC50 values (Carmichael et al., 1987).
2.5. DNA synthesis studies
DNA synthesis was determined using 5-bromo-2-deoxyur-
idine (BrdU) colourimetric incorporation assay (Portsmann
et al., 1985). A-498 and Hep-G2 cells were seeded into 96 well
plates and allowed to adhere overnight. 4-MecdoaH2 or [Cu(4-
Mecdoa)(phen)2] was added and incubated for 96 h prior to the
addition of BrdU (10 μM per well). Plates were then incubated
at 37 °C for 4 h and incorporation was quantified using ELISA
(Roche). The significance of any reduction in DNA synthesis
was determined using one-way ANOVA.
2.6. DNA binding studies
pGEM-3Z plasmid DNAwas purified from Escherichia coli
[strain JM 109 as previously cultured in LB broth (Oxoid),
containing 50 μg/ml ampicillin] using a Qiagen isolation kit
(Qiagen Ltd). DNA purity and concentration was determined
spectrophotometrically using A260/A280 spectrophotometric
measurements. DNA concentration was adjusted to 1 μg/ml
using 10 mM Tris–HCl, pH 7.5, containing 1 mM EDTA. Drug
binding assays were carried out using 4-MecdoaH2 and [Cu(4-
Mecdoa)(phen)2], according to the method described by
Lorcozio and Long (1993). Briefly, DNA was incubated for
2 h at 37 °C, with doxorubicin employed as a positive control.
Plasmid DNAwas separated on a 1% (w/v) agarose gel in TBE
(80 mM Tris–HCl, pH 8; 40 mM boric acid and 2 mM EDTA)
and stained with ethidium bromide (5 μg/ml in TBE). Bands
were visualised by irradiation at 300 nm and photographed
using a Pharmaciae 3D imaging system.
2.7. Morphological analysis
Preparations of Hep-G2 cells exposed to [Cu(4-Mecdoa)
(phen)2] for either 4 or 24 h and stained with methylene blue
and eosin (Freshney, 2004). Drug-treated cells were grown in
petri dishes, washed once with PBS, once with PBS:methanol
(1:1, v/v) and then fixed in 100% (v/v) methanol for 10 min.
Following fixation, cell monolayers were rinsed with anhydrous
methanol and stained with methylene blue and eosin for 2 min.
Monolayers were then agitated for a further 2 min, destained by
rinsing under a gentle stream of water and then finally rinsed
with distilled water. Phase contrast microscopy was carried out
using a Ceti phase contrast microscope.
Cells were also stained using a DNA-binding agent
commonly used to stain nuclei and visualise nuclear morphology
and DNA condensation, namely 4,6-diamidino-2-phenylindole
(DAPI). Briefly, amonolayer of drug-treated cells was washed in
PBS and fixed with 4% (w/v) paraformaldehyde for 30 min at
room temperature. These cells were then permeabilized with
0.2% (v/v) Triton X in PBS and incubated with 1 μg/ml of DAPI
for 30 min. Cells were again washed three times with PBS
and viewed using a fluorescent microscope with 340/380 nm
excitation filter at 250× magnification. Apoptotic cells were
confirmed by identification of intensely stained, fragmented
nuclei and condensed chromatin.
2.8. DNA fragmentation
Chromosomal DNA from drug-treated cells was extracted
using the Suicide-track™ DNA ladder isolation kit (Oncogene).
Briefly, cells were cultured in 150 mm petri dishes and treated
with [Cu(4-Mecdoa)(phen)2] at 0, 6.25, 12.5, and 25 μM for 4
and 24 h. Floating cells were collected by centrifuging, while
adherent cells were harvested by scraping and then combined
with floating cells. All cells were centrifuged and the resulting
pellet consisting of approximately 5×106 cells was resuspended
in 55 μl of lysis solution, followed by the addition of 20 μl of
RNase A solution and incubated at 37 °C in a water bath for 1 h.
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25 μl of DNA isolation solution was added and tubes were
incubated overnight at 50 °C. 500 μl of re-suspension buffer
(10 mM Tris–HCl, pH 7.5, containing 1 mM EDTA) was then
added to each sample. Intact and fragmented DNA was
precipitated by the addition of 2 μl of Pellet-paint™ co-
precipitant followed by 60 μl of 3 M sodium acetate, pH 5.2 and
660 μl of 2-propanol. Samples were mixed by inversion and
then washed once in 70% (v/v) ethanol and once in 100% (v/v)
ethanol. Finally, DNA samples were air-dried and resuspended
in 50 μl of resuspension buffer (10 mM Tris–HCl, pH 6.8)
before analysis on 1.8% agarose gels. Positive controls con-
sisted of 1×106 HL-60 cells (Human leukaemia cells) treated
with 0.5 μg/ml Actinomycin D for 24 h, both supplied by
Oncogene.
2.9. Caspase activity assay
Activation of ICE-family proteases/caspases initiates apo-
ptosis in mammalian cells (Compton, 1992). Hep-G2 cells were
incubated with [Cu(4-Mecdoa)(phen)2] at concentrations of 0,
6.25, 12.5, and 25 μM for 24 h. Both floating and attached cells
were collected by centrifugation and analysed as outlined in
Section 2.8. Cells, at a density of 1.5×106 cells/ml, were
counted, washed with PBS and then re-suspended in chilled cell
lysis buffer (supplied in the Caspase-3 colourimetric assay kit,
Biovision, UK). Cells were incubated on ice for 10 min and then
centrifuged for 1 min at 10,000 ×g. The cytosolic fraction
(supernatant) was collected into a fresh tube and 50 μl (2 mg/
ml) of each protein sample was transferred to a 96-well plate
and diluted with lysis buffer. A 50 μl aliquot of X2 reaction
buffer containing 10 mM DTT was added, followed by 5 μl of
4 mM DEVD-pNA substrate to give a final concentration of
200 μM. The plate was then incubated at 37 °C for 1–2 h. OD
was determined at 400 nm using an Anthos HT-II microti-
treplate reader. The fold increase in caspase-3 and-9 activity was
determined by comparing results to that obtained with un-
induced control.
2.10. Immunoblot analysis for PARP cleavage
Test agent was dissolved in DMSO, diluted in culture media
and used to treat model cells growing in 100 mm petri dishes.
Cells were exposed to [Cu(4-Mecdoa)(phen)2] at concentrations
of 0, 6.25, 12.5 or 25 μM for 24 h. Both floating and attached
cells were collected, as outlined in Section 2.8, and washed
twice with ice-cold 0.1 M PBS, pH 7.4, harvested by scraping,
then centrifuged at 8000 ×g for 5 min. Whole cell extracts were
prepared by re-suspension in lysis buffer [M-per lysing solution
(Pierce, UK)], supplemented to contain 1 mM EDTA, 1 mM
EGTA, 1 mM sodium vanadate, 1 mM phenylmethylsulfonyl
flouride (PMSF), 2 μg/ml leupeptin and 2 μg/ml aprotinin. After
15 min on ice, the mixture was clarified by centrifugation for
5 min at 10,000 ×g and the resultant supernatant collected.
40 μg of total protein lysates were resolved using electropho-
resis on a 12% polyacrylamide gel (PAGE) and transferred to
nitrocellulose membranes. The level of protein expression was
determined using specific primary antibodies, followed by
peroxidase-conjugated secondary antibodies and visualisation
by a chemiluminescent substrate (Luminol) and exposure to X-
ray film.
2.11. Cell cycle analysis
Hep-G2 cells were grown in 100 mm Petri dishes and
exposed to either solvent or [Cu(4-Mecdoa)(phen)2] at
concentrations of 0, 1.5, 3.0, 6.0 μM for 24 h. Both floating
and attached cells were collected by centrifugation (Section
2.8), washed twice in ice-cold PBS, pH 7.4, harvested by
trypsinisation, and then collected by centrifugation. The effect
of drug treatment on cell cycle was determined using flow
cytometric analysis according to the method of Nunez (2001).
Briefly, cell suspensions were fixed and permeabilised by
vigorous addition of nine volumes of ice-cold 70% (v/v) ethanol
and stored at −20 °C for a minimum of 24 h, prior to analysis.
Cells at a density of approximately 1×106 were re-suspended in
800 μl of propidium iodide staining solution (20 μg/ml
propidium iodide and 200 μg/ml RNase A in PBS, pH 7.4)
and incubated in the dark at room temperature for 30 min. The
percentage of cells in the sub-G1, G0/G1, S and G2/M phases of
cell cycle was determined over a range of concentrations and
time points, and analysed from at least three independent
experiments using Cell Quest™ software (Becton Dickinson).
2.12. Statistical analysis
Statistical analyses were performed using the statistical
software package Mini-tab®. Statistical evaluation of the
untreated control cells along with drug-and solvent-treated
cells was calculated using one-way ANOVA (analysis of
variance). A probability of 0.05 or less was deemed statistically
significant. The following notation was used throughout;
⁎Pb0.05, ⁎⁎Pb0.01 and ⁎⁎⁎Pb0.001, relative to control.
3. Results
3.1. Anti-proliferative and cyto-selective properties
4-MecdoaH2 and [Cu(4-Mecdoa)(phen)2] shown in Fig. 1,
along with 1,10-phenanthroline, cisplatin and Cu(ClO4)2 were
initially incubated with four human-derived cell lines, two
carcinoma (A-498 and Hep-G2) and two non-carcinoma
(CHANG and HK-2), and the anti-proliferative effect deter-
mined using MTT. Data obtained for 4-MecdoaH2 and [Cu(4-
Mecdoa)(phen)2] following 4, 24 and 96 h continuous
incubation was used to calculate IC50 values and are shown in
Figs. 2 and 3, along with Table 1. All compounds displayed a
concentration-and time-dependent anti-proliferative profile, and
in all four cell lines. Hep-G2 cells appeared to be the most
sensitive. Also, based on both the dose response curve (Figs. 2
and 3) and the IC50 value calculated, it would appear that [Cu(4-
Mecdoa)(phen)2] was statistically more active than the either
the parent ligand or 1,10-phenanthroline (Table 1). In order to
prove that the cytotoxicity observed was due to the complex
rather than the simple copper salt, it was decided to include Cu
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(ClO4)2 in the test protocol. The data presented in Table 1
suggests that CuClO4 is not capable of displaying cytotoxicity
below 250 μM in any of the model cell lines. In addition, we
investigated the possibility that these agents could act as a
potent anti-proliferative agent in neoplastic-derived (Hep-G2
and A-498) rather than non-neoplastic-derived (CHANG and
HK-2) cell lines. The results presented in Table 1 would suggest
that Hep-G2 cells were significantly more sensitive than
CHANG, but this effect was not reflected in the non-neoplastic
renal HK-2 cells. Thus, there is insufficient evidence to
conclude that the complex can act in a cyto-selective manner,
i.e. that is capable of sparing non-neoplastic cells. However, it is
worth noting that the complex displayed a profile similar to that
seen with cisplatin. Furthermore, the IC50 values obtained for
cisplatin were shown to be between 7 and 11.5 times greater in
the two neoplatic model cell lines, A-498 and Hep-G2,
respectively. Taken together, the data presented would suggest
that the complex was capable of exhibiting a similar in vitro
anti-proliferative profile to that of cisplatin.
In order to provide information on the anti-proliferative
effect of this complex following relatively short exposure times,
MTT-based viability assays were conducted at both 4 and 24 h
and the IC50 was calculated to be 55 and 12 μM, respectively,
for the most sensitive cell line, Hep-G2 (Fig. 3). Consequently,
these concentrations and time-points were selected for inclusion
in all subsequent assays unless otherwise stated, and used to
probe the molecular mechanism of action of the complex.
It has been established that over-expression of P-glycopro-
tein-170 is responsible for the “classical” type of multi-drug
resistance. This has been defined as the simultaneous resistance
of a cell against a variety of structurally dissimilar cytotoxic
drugs (Gottesmann et al., 1996; Tellingen, 2001). Using a
cellular model of MDR-1, we confirmed the multi-drug resistant
phenotype by immunological detection of P-glycoprotein-170
along with chemosensitivity testing using vinblastine. This
method allows the multi-drug resistant phenotype to be assessed
by detection of the protein effector molecule and by comparison
of the relative toxicities (IC50) in the multi-drug resistant
positive and negative cell lines. Consequently, drugs that
display lesser or equal effects in the multi-drug resistant positive
cell line could be potential multi-drug resistant substrates.
Furthermore, comparison of the relative experimental toxicities
allows calculation of a resistance factor. This factor was
calculated by dividing the drug toxicity (IC50 value) observed in
the multi-drug resistant positive cells by the drug toxicity in the
multi-drug resistant negative cells. In addition, the integrity of
the two model cells lines was confirmed by Western blot
Table 1
Anti-proliferative activity of test agents was determined using Hep-G2,
CHANG, A-498 and HK-2 cells, following 96 h continuous incubation, and
MTT assay
Compound Hep-G2 CHANG A-498 HK-2
IC50 (mM)±
S.E.M.
IC50 (mM)±
S.E.M.
IC50 (mM)±
S.E.M.
IC50 (mM)±
S.E.M.
4-MecdoaH2 N250 N250 N250 N250
[Cu(4-Mecdoa)
(phen)2]
1.3±0.8a 11±1.8a 2.0±1.2a 2.8±0.8a
Cu(ClO4)2 N250 N250 N250 N250
1,10-phenanthroline 4.5±0.9 7±1.2 5.5±1.2 9±1.5
Cisplatin 15.0±2.6 45±2.9 14.0±2.3 18±2.7
aIndicates that value is statistically distinct from that of the parent ligand at
Pb0.05.
A graph of viability versus drug concentration was used to calculate all IC50
values (μM), n=5.
Fig. 3. Dose response curves for [Cu(4-Mecdoa)(phen)2] using Hep-G2 cells
following 4 and 24 h incubation, as assessed by MTT assay. This complex
caused a concentration-and time-dependent decrease in cellular proliferation.
Results are expressed as percentage viability of solvent-treated control cells.
Bars indicate±S.E.M., n=3.
Fig. 2. Dose response curves for 4-MecdoH2, 1,10-phenanthroline and [Cu(4-
Mecdoa)(phen)2] using (A) Hep-G2 and (B) A-498 cells, following 96 h
incubation, as assessed by MTT assay. In both cases, the complex produced the
greatest concentration-dependent decrease in cellular proliferation, following
96 h incubation. Results are expressed as percentage viability of solvent-treated
control cells. Bars indicate±S.E.M., n=3.
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analysis. P-glycoprotein-170 was not detected in the multi-drug
resistant negative cells (CHOK1), while there was considerable
P-glycoprotein-170 expression in multi-drug resistant positive
cells (CHRC5) (data not shown). In addition, the results
presented in Table 2 show the data obtained for vinblastine
and the test complex. These results indicate that the multi-drug
resistant phenotype of CHRC5 cells was retained, and that
vinblastine demonstrated a resistance factor of 37. This value is
consistent with a previously published value of 40 (Finn et al.,
2004b). In contrast, data obtained for the complex illustrated a
substantially lower resistance factor, suggesting that the
complex is not a potential MDR-1 substrate. In addition,
greater cytotoxicity was observed in the multi-drug resistant
positive cell line, rather than the multi-drug resistant negative
cell line (Table 2).
3.2. Inhibition of DNA synthesis and intercalation
In an attempt to elucidate the events responsible for the
observed reduction in cellular proliferation, the effect of 4-
MecdoaH2 and [Cu(4-Mecdoa)(phen)2] on DNA synthesis was
determined using BrdU incorporation assays. Results obtained
suggest that [Cu(4-Mecdoa)(phen)2] caused a dose-dependent
decrease in DNA synthesis, across the two model neoplastic cell
lines, Hep-G2 and A-498 (Fig. 4).
In order to explore the relationship between the observed
cytotoxic response and the possibility that DNA was a
molecular target, intercalation studies were carried out using
electrophoretic mobility shift assays. Treatment of pGEM-3Z
plasmid DNA with the complex at concentrations of 1, 10 and
200 μM did not alter the migration of any of the three forms of
DNA (super-coiled, linear or open-circular), unlike the positive
control doxorubicin (Fig. 5). This indicates that [Cu(4-Mecdoa)
(phen)2] does not function through DNA intercalation.
3.3. Morphological analysis and induction of cleaved PARP
The cytological effects of treatment with the complex at
concentrations of 0, 6.25, 12, and 25 μM for either 4 or 24 h
were determined using methylene blue and eosin (Fig. 6), along
with DAPI staining (Fig. 7) and standard light microscopy. The
results presented in Fig. 6 clearly suggest that [Cu(4-Mecdoa)
(phen)2] at 4 and 24 h and a concentration of 25 μM (panel D)
caused nuclear disintegration and vacuolation of the cytoplasm.
These changes are generally considered to be characteristic of
the induction of both apoptotic and necrotic cell death. In
contrast, treatment of cells with vehicle alone (Fig. 6 A)
appeared to have no visible effect, as cells retained the typical
epithelial morphology associated with Hep-G2 cells.
Table 2
Anti-proliferative activity and resistance factor used to confirm multi-drug
resistance phenotype and demonstrating whether [Cu(4-Mecdoa)(phen)2] was a
substrate for P-glycoprotein
Test agent CHO-K1 CHRC5 Resistance
factor
IC50 (μM)±S.E.M. IC50 (μM)±S.E.M.
[Cu(4-Mecdoa)(phen)2] 4.13±0.50 3.56±0.35 0.09
Vinblastine 0.013±0.005 0.48±0.04 37
The resistance factor was calculated by division of the IC50 for the CH
RC5 cell
line by the IC50 for the CHO-K1 cell line. Results presented are representative of
three independent experiments.
Fig. 4. The effects of 4-MecdoaH2 and [Cu(4-Mecdoa)(phen)2] on DNA
synthesis in both (A) A-498 and (B) on Hep-G2 cells was determined using
BrdU assays. Both compounds produced a dose-dependent decrease in DNA
synthesis, and in both cell lines following 96 h incubation. Results are expressed
as percentage viability of solvent-treated control cells. Bars indicate±S.E.M.,
n=3.
Fig. 5. Electrophoretic mobility shift assays were used to determine the effects of
4-MecdoaH2 and [Cu(4-Mecdoa)(phen)2] on the migration of pGEM-3Z
supercoiled plasmid DNA for 2 h at 37 °C, analysed by agarose electrophoresis
and stained with ethidium bromide. Results indicate that neither compound
inhibited migration of super coiled (SC), linear (L), or open circular (OC) forms
of plasmid DNA, suggesting they do not intercalate DNA. Lane 1 pGEM-3Z
DNA (negative control); lane 2 positive control (pGEM-3Z DNA and
doxorubicin, 10 μM); lanes 3–5 pGEM-3Z DNA and 4-MecdoaH2 (1, 10,
and 200 μM); and lanes 6–8 pGEM-3Z DNA and [Cu(4-Mecdoa)(phen)2] (1,
10, and 200 μM).
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The effect of the complex on the integrity of DNAwas then
determined using DAPI. This stain is commonly used to
visualise nuclear morphology and detect the presence of DNA
condensation. Results presented in Fig. 7 show that following
4 h, cells exposed to 6.25 and 12.5 μM caused nuclear shrinkage
(panels B and C, respectively). In contrast, a concentration of
25 μM caused nuclei to become enlarged (panel D).
Furthermore, by 24 h, and at concentrations of 6.25, 12.5 and
25 μM, nuclei become enlarged, intensively stained, and
nuclear material appeared fragmented (panels B to D,
respectively). Taken together, these results suggest the presence
of both apoptotic and necrotic cell death.
Analysis of DNA from apoptotic cells by agarose electro-
phoresis is known to produce a characteristic DNA ladder that is
widely regarded as a biochemical hallmark of apoptosis.
Therefore, in order to further clarify the results observed in
both Figs. 6 and 7, genomic DNA was extracted from drug-
treated cells. Both floating and attached cells were collected for
electrophoriesis. Results presented in Fig. 8 illustrate that the
complex was capable of inducing an increase in 180 base-pair
multimeric bands. Furthermore, it appears that increasing drug
concentration may have caused band smearing, suggesting the
presence of necrotic cell death. Finally, it is worth noting that no
DNA fragmentation was observed following 4 h incubation
Fig. 6. The effect of [Cu(4-Mecdoa)(phen)2] on the cellular morphology of Hep-G2 cells, as assessed by methylene blue and eosin staining, using phase contrast
microscopy (60× magnification). Cells were treated with complex for 4 or 24 h at concentrations of 0, 6.25, 12.5 and 25 μM (panels A–D, respectively). [Cu(4-
Mecdoa)(phen)2] at a concentration of 25 μM and at 4 and 24 h incubation, resulted in a visible thinning of the monolayer, with nuclear disintegration, and vacuolation
of the cytoplasm (panel D). Control cells (panel A) treated with vehicle alone retained the typical epithelial morphology associated with Hep-G2 cells.
Fig. 7. The effect of [Cu(4-Mecdoa)(phen)2] on the cellular morphology of Hep-G2 cells, as assessed by methylene blue and eosin staining, using phase contrast
microscopy (60× magnification). Cells were treated with complex for 4 or 24 h at concentrations of 0, 6.25, 12.5 and 25 μM (panels A–D, respectively). [Cu(4-
Mecdoa)(phen)2] at concentration of 25 μM and at 4 and 24 h, resulted in a visible thinning of the monolayer, with nuclear disintegration, and vacuolation of the
cytoplasm (panel D). Control cells (panel A) treated with vehicle alone retained the typical epithelial morphology associated with Hep-G2 cells.
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(data not shown), suggesting that a period greater than 4 h and
maybe as long as 24 h may be required to produce the observed
effects.
3.4. Biochemical assays to detect cell death
Caspase-3 is known to be one of the main executioner/
effector caspases which is activated by caspase-9 (Compton,
1992). The results presented in Fig. 9 show the fold increase in
both caspase-3 and-9 activities following 24 h incubation. The
activity of both of these enzymes was significantly increased as
a result of exposure to [Cu(4-Mecdoa)(phen)2] at concentrations
of 12.5 and 25 μM, but not at the lower concentration of
6.25 μM.
The results presented in Fig. 9 suggests that if apoptosis were
to be caspase-dependant there would be a corresponding
increase in cleavage of poly(ADP-ribose)-polymerase protein
(PARP), a known consequence of caspase-3 activation. This
theory was subsequently confirmed using Western Blot Analy-
sis (Fig. 10), where [Cu(4-Mecdoa)(phen)2] at test concentra-
tions of 12.5 and 25 μM was seen to increase the expression
of cleaved PARP. However, this increase was not seen at the
lower concentration of 6.25 μM (data not shown). Taken
together with the results obtained from the caspase assays, it
would indicate that concentrations of 12.5 and 25 μM are
capable of inducing caspase-dependent apoptotic cell death
through activation of caspases-3 and-9, with subsequent
cleavage of PARP.
3.5. Inhibition of cell cycle progression
The effect of the complex on cell cycle events was examined
and the resultant histograms were studied for evidence of
apoptotic cell death. Hep-G2 cells were exposed to test agent
(1.5, 3 and 6 μM) for 24 h and the percentage of cells entering
each phase of the cell cycle was determined. Examination of the
histograms (Fig. 11A) indicated the presence of a sub-G1 peak
which increased with increasing drug concentrations of 3 and
6 μM. Exposed of cells to a concentration of 6 μM, lead to a
dramatic increase in the % of cells displaying a sub-G1 peak. It
should be noted that a similar concentration did not produce a
Fig. 8. Internucleosomal DNA cleavage in Hep-G2 cells treated with [Cu(4-
Mecdoa)(phen)2] was determined following growth in the presence of either
vehicle or complex (lanes 3–5 at concentrations of 6.25, 12.5 and 25 μM) for
24 h. Both floating and attached cells were collected by centrifugation and
fragmented and intact genomic DNA was extracted using the Suicide-track™
DNA ladder isolation kit. DNA were separated using agarose electrophoresis
and stained using ethidium bromide. Drug treatment resulted in an increase in
180 base-pair multimeric bands. Furthermore, it appeared that increasing drug
concentration may cause band smearing (lanes 4 and 5). Lane 1 consisted of the
positive control provided in the kit consisting of 1×106 HL-60 cells (human
leukaemia cells) treated with 0.5 μg/ml Actinomycin D for 24 h, while lane 2
consisted of a negative control treated with vehicle alone.
Fig. 9. The effects of [Cu(4-Mecdoa)(phen)2] on caspase-3 and-9 activity was
determined using a colorimetric protease assay. Hep-G2 cells were treated with
complex at concentrations of 0, 6.25, 12.5 and 25 μM for 24 h. Both floating and
attached cells were collected and analysed. Cells were lysed and the protein
concentration was diluted to 1 mg/ml. The fold-increase in the activity of
caspases-3 and-9 was determined by comparison with that of the vehicle control.
Drug treatment at 12.5 and 25.0 μM resulted in a statistically significant dose-
dependent increase in the activity of both caspases. Results obtained are
representative of three independent experiments. Bars indicate±S.E.M. The
asterisks indicate statistically significant differences to control: ⁎Pb0.05 and
⁎⁎Pb0.01.
Fig. 10. The effect of [Cu(4-Mecdoa)(phen)2] on the proteolytic cleavage of
poly(ADP-ribose)polymerase (PARP) was determined using Hep-G2 cells,
following 24 h incubation. Both floating and attached cells were collected and
analysed. A band corresponding to cleaved PARP (85 kDa) was detected
following concentrations of 12.5 and 25 μM (panel A, lanes 1 and 2,
respectively), unlike 6.25 μM (data not shown). The same lysates were probed
for the presence of β-actin (45 kDa) as a normalisation control (panel B).
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statistically significant increase in the activity of caspase-3 and-
9 (Fig. 9). Furthermore, the results presented in Fig. 11 B show a
concentration-dependent decrease in the % of cells entering G0/
G1 and G2/M. In addition, the % in S phase increased at the
lower drug concentrations and subsequently decreased at the
highest concentration studied. Finally, the histograms presented
in Fig. 11 B would indicate that Hep-G2 cells may be
polyploidy. We suggest that this is likely to be due to cell
clustering resulting from a difficulty in preparation of a single
cell suspension, rather than any effect of the complex, as this
was also present in solvent-treated control cells.
4. Discussion
The primary objective of this study was to identify the anti-
proliferative properties of a bis(phenanthroline 4-methylcou-
marin-6,7-dioxyacetatocopper(II) complex, namely [Cu(4-Mec-
doa)(phen)2]. We also attempted to determine whether this
complex could selectively kill human cancer cells, leaving non-
neoplastic cells viable. In addition, we sought to elucidate the
molecular mechanism underlying the pharmacology of this
compound. In order to highlight the potential advantage of this
compound, comparative studies were carried out using one of
the best known and most widely used metal-based anti-cancer
drugs, cisplatin. Furthermore, this is the first study of its kind to
determine the potential application of this complex as a novel
anti-proliferative agent.
Initial cytotoxicity studies were carried out to determine the
IC50 value for each test agent, along with the simple metal salt
Cu(ClO4)2, 1,10-phenanthroline and cisplatin, using all four
human-derived model cell lines. It was intended that this
approach would allow us to determine if the observed anti-
proliferative effect was due to the entire copper–coumarin–
phenanthroline complex, rather than the metal-free ligand, 1,10-
phenanthroline or the simple aquated copper metal ion.
Additionally, through the use of two pairs of hepatic and renal
cells lines, one derived from neoplastic origin and the other
from non-neoplastic, it was hoped that this might provide a
means by which the potential selective nature of the complex
could be identified. The results obtained from the initial via-
bility studies (Figs. 2 and 3, along with Table 1) showed that
following 4, 24 and 96 h exposure, the complex displayed both
concentration-and time-dependant anti-proliferative effect. In
addition, based on IC50 values presented in Table 1, it appeared
that the complex was more active than the metal-free ligand,
1,10-phenanthroline or the metal salt or cisplatin. Furthermore,
Hep-G2 cells were shown to be most sensitive, with the
complex being 11 times more active than cisplatin. The results
obtained also suggest that Hep-G2 cells were significantly more
sensitive than CHANG, but this effect was not seen with the
non-neoplastic renal (HK-2) cells. Consequently, it would
appear that like cisplatin, the complex is capable of reducing
the proliferative capacity of cells, but not in a cyto-selective
manner. The concentrations and time points chosen for sub-
sequent assays were selected on the basis that they represented
IC50, half the IC50, and finally double the IC50 at 24 h. In this
way, the relatively short-term effects of the complex could be
determined.
Fig. 11. The effect of [Cu(4-Mecdoa)(phen)2] on cell cycle progression was determined following incubation for 24 h with concentrations of 1.5, 3 and 6 μM. Both
floating and attached cells were collected and analysed. Cells were harvested, alcohol-fixed and stained with propidium iodide. Cell cycle distribution was determined
by calculating the percentage of cells in each phase of the cell cycle (panel B), using flow cytometric analysis. Results show a dose-dependant disruption in phase
progression, with the appearance of a sub-G1 peak (panel A), representative of hypodiploid DNA content. Histograms obtained are representative of three independent
experiments.
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The morphology of drug-treated cells was used to determine
the extent and nature of cytological effects. Two different
staining techniques were employed. Firstly, cells were stained
using methylene blue and eosin in order to determine if gross
morphological changes could be observed, while the second
stain used was DAPI. This latter stain is specific for visual-
isation of nuclear morphology and detection of DNA con-
densation. Results presented in Figs. 6 and 7 clearly show that
the complex could induce changes which were consistent
with the induction of both apoptotic and necrotic cell death. In
addition, it would appear that the mode of cell death was
dependent on both drug concentration and incubation time, with
higher doses and longer incubations times required to switch
from apoptosis to necrosis.
In an attempt to provide evidence for the involvement of
many of the biochemical processes which are central to
controlling the underlying mechanisms, it was decided to
study of number of key features of cell death. Therefore,
additional studies were carried out using genomic DNA isolated
from drug-treated cells. Cleavage of genomic DNA by
endogenous endonucleases during apoptosis is an irreversible
event that commits the cell to die (Blatt and Click, 2001). The
results presented in Fig. 8 show that by 24 h, drug-treated cells
had activated the necessary endonucleases, such that endonu-
cleolytic cleavage of DNA at internucleosomal linker sites had
occurred, leading to the production of 180–200 bp mono-and
oligo-nucleosomal fragments. In addition, increasing drug
concentration caused band smearing, suggesting the possible
indication of necrotic cell death. This finding served to underpin
the morphological results obtained by DAPI staining (Fig. 7).
It is now widely accepted that activation of the caspase
cascade occurs upstream of DNA fragmentation (Compton,
1992; Kuribayashi et al., 2006). This activation serves to induce
the proteolytic cleavage of a wide range of substrates. Caspase-3
is known to cleave and inactivate the inhibitor of caspase-
activated DNAase, which in turn causes the release of active
endonucleases which translocate into the nucleus in order to
activate internucleosomal DNA fragmentation, ultimately
serving as a trigger for phagocytosis (Compton, 1992; Nagata,
2000). In addition, caspase-3 activation leads to increased
cleavage of PARP, a known substrates for caspase-3 (Nagata,
2000). Proteolytic cleavage of native PARP (116 kDa) results in
separation of the N-terminal binding domain (24 kDa) from its
C-terminal catalytic domain (89 kDa), (Kartner et al., 1993;
Yang et al., 2006). This is also an early critical event required for
tumour cells that have been exposed to DNA-damaging agents
and have committed to die by apoptosis. Therefore, we decided
to investigate the involvement of caspase-3 and-9 in the action of
the complex (Fig. 9). Data obtained demonstrates that the
complex could mediate the activity of both caspase-3 and-9
leading to PARP cleavage. Taken together, these results
indicated that the complex, at high concentrations (12.5 and
25 μM) could cause caspase and PARP-dependent cell death.
The ability of the complex to target DNA through an
inhibition of synthesis was also determined (Fig. 4). We have
shown (Fig. 5) that it was non-intercalative, but that it was
capable of decreasing DNA synthesis. Based on the finding
presented here, we were confident that the effect on DNA
synthesis was linked, not just to an anti-proliferative effect, but
also to the machinery associated with cell division, and
ultimately an ability to induce cell death. We decided to use
flow cytometric analysis to investigate the effect on both cell
division and death. Consequently, Hep-G2 cells were exposed
to test agent (1.5, 3 and 6 μM) for 24 h and the percentage of
cells entering each phase of the cell cycle was determined. This
finding suggested that the complex was capable of preventing
cell cycle progression. It is now widely established that
progression is a tightly ordered and regulated process involving
multiple checkpoints. These checkpoints respond to a variety of
growth signals, alterations in cell size and DNA integrity
(Garrett et al., 2001; Giacinti and Gioradano, 2006; Tao and
Lin, 2006). We postulate that the complex may act on these
checkpoints, preventing further cell division and subsequently
initiating death by apoptosis and/or necrosis. However, this
theory has not yet been proven experimentally. It is worth
noting that the test concentrations used in this part of the study
were substantially lower than before. These lower concentra-
tions were chosen as higher concentrations (12.5 and 25 μM)
lead to a complete degradation of DNA, making it impossible to
determine effects on the cell cycle. This suggested that when
cells were exposed to higher drug concentrations, they may
undergo necrotic cell death, and by a mechanism which was
caspase-dependent (Fig. 9). This theory may help explain the
findings presented in Fig. 7, using DAPI staining, where cells
display characteristics consistent with necrotic cell death.
Examination of the flow cytometric histograms (Fig. 11 A)
indicated the presence of a sub-G1 peak which increased with
increasing drug concentration (6 μM). However, this concen-
tration did not produce a statistically significant increase in
caspase-3 and-9 activity (Fig. 9). Taken together, this would
suggest that cell death may occur via a caspase-independent
mechanism with concurrent blockage in cell cycle events.
Recently, caspase-independent apoptosis has been observed in
several cell types (Carmody and Cotter, 2001: Marzo et al.,
2001; Loeffler et al., 2002; Ahn et al., 2004). Researchers have
shown that one of the proteins responsible for caspase-
independent chromatin condensation is apoptosis-inducing
factor (AIF) (Susin et al., 1999). AIF is a 57 kD flavoprotein
which is confined to the mitochondrial intermembrane space of
healthy cells. However, upon exposure to lethal agents, AIF
translocates from the mitochondria to the nucleus, via the
cytosol. Although this protein may induce caspase-independent
peripheral chromatin condensation and large-scale DNA
fragmentation, the molecular signalling mechanism remains to
be identified. Consequently, the possibility remains that that the
complex studied here may function through AIF.
In conclusion, the results from this study clearly indicate that
[Cu(4-Mecdoa)(phen)2], rather than either the parent ligand 4-
MeCdoaH2, 1,10-phenanthroline or the simple salt, could act as
a potent anti-proliferative agent. However, there is insufficient
evidence to suggest that it could function in a cyto-selective
manner. Additionally, we have shown that this complex can
induce morphological and biochemical features consistent
with the induction of both apoptotic and necrotic cell death.
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However, concentration of the complex may be one of the main
factors which causes a cell to switch between the two modes of
death. Additional studies are currently underway by which both
the number of apoptotic cells can be accurately quantified and
the role of regulatory proteins associated with cell division and
death can be determined more fully. Furthermore, we intend to
elucidate the inter-relationship between these regulatory
proteins and those associated with signalling proteins, such as
the mitogen-activated protein kinases which are known to
control cellular proliferation, death and differentiation (Hoshino
et al., 2001). It is hoped that results from these studies will allow
the identification of additional molecular targets, which may
further assist in the elucidation of the mechanism of action of
this complex.
Acknowledgements
This research was supported by the Technological Sector
Research Programme, Strand III (2002–2005), under the
European Social Fund. The research was carried out by the
Centre for Pharmaceutical Research and Development (CPRD)
jointly located at Institutes of Technology, Tallaght and Dublin,
and the National University of Ireland, Maynooth, Co. Kildare,
Ireland. The authors would also like to express gratitude to Dr.
Brian A. Murray for his editorial support during the preparation
of this manuscript.
References
Ahn, H.J., Kim, Y.S., Kim, J.U., Han, S.M., Shin, J.W., Yang, H.O., 2004.
Mechanism of taxol-induced apoptosis in human SKOV3 ovarian carcinoma
cells. J. Cell. Biochem. 91, 1043–1052.
Blatt, N.B., Click, G.D., 2001. Signalling pathways and effector mechanisms:
pre-programmed cell death. Bioorg. Med. Chem. 9, 1371–1384.
Butler, H.M., Hurse, A., Thursky, E., Shulman, A., 1969. Bactericidal action of
selected phenanthroline chelates and related compounds. Aust. J. Exp. Biol.
Med. Sci. 47, 541–552.
Carmichael, J., De Graf, G., Gadzar, A., Minna, J., Mitchell, J., 1987. Evaluation
of a tetrazolium-based colorimetric assay: assessment of chemosensitivity
testing. Cancer Res. 47, 936–942.
Carmody, R.J., Cotter, T.G., 2001. Signalling apoptosis: a radical approach.
Redox Rep. 6, 77–90.
Compton, M.M., 1992. A biochemical hallmark of apoptosis: internucleosomal
degradation of the genome. Cancer Metastasis Rev. 11, 105–112.
Coyle, B., McCann, M., Kavanagh, K., Devereux, M., Geraghty, M., 2003.
Mode of antifungal activity of 1,10-phenanthroline and its Cu(II), Mn(II)
and Ag(I) complexes. BioMetals 16, 321–329.
Creaven, B.S., Egan, D.A., Kavanagh, K., McCann, M., Mahon, M., Noble, N.,
Thati, B., Walsh, M., in press. Synthesis, characterisation, and antimicrobial
activity of copper(II) and manganese(II) complexes of coumarin-6,7-
dioxyacetic acid and 4-methylcoumarin-6,7-dioxyacetic acid: X-ray crystal
structures of the phenanthroline adducts [Cu(cdoa)(phen)2]·8.8H2O and [Cu
(4-Mecdoa)(phen)2]·13H2O (phen=1,10-phenanthroline). J. Inorg. Bio-
chem. (Man no.: JIB 06-1003) (Available online, 4th May 2007).
Deegan, C., McCann, M., Devereux, M., Coyle, B., Egan, D.A., 2007. In Vitro
chemotherapeutic potential and mechanism of action of 1,10-Phenanthroline
(phen), [Ag2(phen)3(mal)]·2H2O, [Cu(phen)2(mal)]·2H2O and [Mn(phen)2
(mal)]·2H2O (malH2=malonic acid), using human cancer cells. Cancer Lett.
247, 224–233.
Dwyer, F.P., Reid, I.K., Shulman, A., Laycock, G.M., Dixon, S., 1969. The
biological actions of 1,10-phenanthroline and 2,2′-bipyridine hydrochlor-
ides, quaternary salts and metal chelates and related compounds.
Bacteriostatic action on selected gram-positive, gram-negative and acid-
fast bacteria. Aust. J. Expt. Biol. Med. Sci. 47, 203–218.
Egan, D.A., O'Kennedy, R., Moran, E., Thornes, R.D., 1990. The pharmacol-
ogy, metabolism, analysis and applications of coumarin and coumarin-
related compounds. Drug Metab. Rev. 22, 503–529.
Egan, D.A., James, P., Cooke, D., O'Kennedy, R., 1997. Studies on the
cytostatic and cytotoxic effects and mode of action of 8-nitro-7-
hydroxycoumarin. Cancer Lett. 118, 201–211.
Finn, G.J., Creaven, B.S., Egan, D.A., 2001. Study of the in vitro cytotoxic
potential of natural and synthetic coumarin derivatives using human normal
and neoplastic skin cell lines. Mel. Res. 11, 461–476.
Finn, G.J., Creaven, B.S., Egan, D.A., 2004a. A study of the role of cell cycle
events mediating the mechanism of action of coumarin derivatives in human
malignant melanoma cells. Cancer Lett. 214, 43–54.
Finn, G.J., Creaven, B.S., Egan, D.A., 2004b. Daphnetin-induced differentiation
of human renal carcinoma cells and its mediation by p38 mitogen-activated
protein kinase. Biochem. Pharmacol. 67, 1779–1788.
Finn, G.J., Creaven, B.S., Egan, D.A., 2005a. Effects of coumarin derivatives on
differentiation of melanotic melanoma cells: a functional role for mitogen-
activated protein kinases. Eur. J. Pharm. Sci. 26, 16–25.
Finn, G.J., Creaven, B.S., Egan, D.A., 2005b. Activation of mitogen protein
kinase pathways and melanogenesis by novel nitro-derivatives of 7-
hydroxycoumarin in human malignant melanoma cells. Eur. J. Pharm. Sci.
26, 16–25.
Freshney, R.I., 2004. Culture of animal cells; a manual of basic techniques, 3rd
Edition. Wiley-Liss, New York, USA, p. 382.
Fricker, P.S., 1994. Metal compounds in cancer therapy; in “The role of metals
in cancer therapy”. Chapman and Hall, London, UK, pp. 10–15.
Garrett, S., Barton, W.A., Knights, R., Jin, P., Fischer, R.P., 2001. Reciprocal
activation by cyclin-dependent kinases 2 and 7 is directed by substrate
specificity determinants outside the T loop. Mol. Cell. Biol. 21 (1), 88–99.
Giacinti, C., Gioradano, A., 2006. RB and cell cycle progression. Oncogene 25
(38), 5220–5227.
Gottesmann, M.M., Pastan, I., Ambukar, S.V., 1996. P-glycoprotein and multi-
drug resistance. Curr. Opin. Gene 6, 610–617.
Hamilton, C., Winker, M., Louie, K., Batist, G., Behrens, B., Tsuruo, T.,
Grotzinger, K., McKoy, W., Young, R., Ozols, R., 1985. Augmentation of
adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and-
sensitive human ovarian carcinoma cell lines by buthionine sulfoximine-
mediated glutathione depletion. Biochem. Pharmacol. 34, 2583–2586.
Hayes, J.D., Pulford, D.J., Ellis, E.M., McLeod, R., James, R.F.L., Seidegard, J.,
Mosialou, E., Jernstrom, B., Neal, G.E., 1998. Regulation of rat glutathione
S-transferase A5 by cancer chemopreventative agents: mechanisms of
inducible resistance to aflatoxin B1. Chem.-Biol. Interact. 111, 51–67.
Heffeter, P., Jakupec, M.A., Korner, P., Chiba, Dornetshuber, R., Elbling, L.,
Sutterluty, H., Micksche, M., Keppler, B.H., Berger, W., 2006. Enhanced
anticancer activity of [tris(1,10-phenanthroline)lanthanum(Ш)trithiocyanate
(KP772; FFC24) against ABC-transporter-overexpressing cells. Eur. J.
Cancer, Suppl. 4 (12), 57.
Hoffmanova, J., Kozubik, A., Dusek, L., Pachernik, P., 1998. Inhibitors of
lipoxygenase metabolism exert synergistic effects with retinoic acid on
differentiation of human leukaemia HL-60 cells. Eur. J. Pharm. 350, 273–284.
Hoshino, R.S., Tanimura, K., Wanatabe, T., Kataloa, T., Kohno, M., 2001.
Blockade of the extracellular signal-regulated kinase pathway induces
marked G1 cell cycle arrest and apoptosis in tumour cells in which the
pathway is constitutively activated. J. Biol. Chem. 276, 2686–2692.
Hoult, R.J.S., Paya, M., 1996. Pharmacological and biochemical actions of
simple coumarins: natural products with therapeutic potential. Gen.
Pharmacol. 27, 713–722.
Jimenez-Orozco, F.A., Molina-Guarneros, J.A., Mendoza-Patino, N., Leon-
Cedeno, F., Flores-Perez, B., Santos-Santos, E., Mandoki, J.J., 1999.
Cytostatic activity of coumarin metabolites and derivatives in the B-16-F10
murine melanoma cell line. Mel. Res. 9, 243–247.
Kartner, N., Denoyers, S., Ottovian, Y., Davidson, N.E., Poirier, G.G., 1993.
Specific proteolytic cleavage of poly(ADP ribose)polymerase: an early
indicator of chemotherapy-induced apoptosis. Cancer Res. 53, 3976–3985.
Kimura, Y., Okuda, H., Arichi, S., Baba, K., Kozawa, M., 1985. Inhibition of the
formation of 5-hydroxy-6,8,11,14-eicosatetraenoic acid from arachidonic
27B. Thati et al. / European Journal of Pharmacology 569 (2007) 16–28
acid in polymorphonuclear leukocytes by various coumarins. Biochim.
Biophys. Acta 834, 224–229.
Kokotos, G., Theodoru, V., Tzougraki, C., 1997. Synthesis and in vitro
cytotoxicity of aminocoumarin platinum(II) complexes. Bioorg. Med.
Chem. Lett. 7, 2165–2168.
Kolodziej, H., Kayser, O., Woerdenbag, H.J., Van, W., Ulden, W., Pras, N.,
1997. Structure-cytotoxicity relationships of a series of natural and semi-
synthetic simple coumarins as assessed in two human tumour cell lines.
Naturforschung 52, 240–244.
Kostova, I., Manalov, I., Karaivanova, M., 2001. Synthesis, physiochemical
characterisation and cytotoxic screening of new zirconium complexes with
coumarin derivatives. Arch. Pharm. 334, 157–162.
Kuribayashi, K., Mayes, P.A., El-Deiry, W.S., 2006. What are Caspases 3 and 7
doing upstream of the Mitochondria? Cancer Biol. Ther. 5, 763–765.
Laurin, P., Klich,M., Dupis-Hamelin, C., Mauvais, P., Lassaigne, P., Bonnefoy, A.,
Musicki, B., 1999. Synthesis and in vitro evaluation of novel highly potent
coumarin inhibitors of gyrase B. Bioorg. Med. Chem. Lett. 9, 2079–2084.
Linder, M.C., 2001. Copper and genomic stability in mammals. Mutat. Res. 475,
141–152.
Loeffler, M., Daugas, E., Susin, S.A., Zamzami, N., Metivier, D., Nieminen, A.L.,
Brothers, G., Penninger, J.M., Kroemer, G., 2002. Dominant cell death
induction by extramitochondrially targeted apoptosis-inducing factor. FASEB
J. 215, 76–78.
Lorcozio, A., Long, B.H., 1993. Biochemical characterisation of elasamicin and
other coumarin-related antitumour agents as potent inhibitors of human
topoisomerase II. Eur. J. Cancer 29, 1985–1991.
MacLeod, R.D., 1952. The toxicity of o-phenanthroline for lactic acid bacteria.
J. Biol. Chem. 197, 751–761.
Manalov, I., Kostova, I., Netzeva, T., Konstantinova, S., Karaivanova, M., 2002.
Cytotoxic activity of cerium complexes with coumarin derivatives. Arch.
Pharm. Med. Chem. 333, 93–98.
Marshall, M.E., Mendelshon, L., Butler, K., Wiseman, C., Harvey, J.,
MacDonald, S.J., 1986. Treatment of metastatic melanoma with coumarin
and cimetidine. Am. Soc. Oncol. 5, 186.
Marshall, M.E., Ryles, M., Butler, K., Weiss, L., 1994. Treatment of advanced
renal cell carcinoma (RCC) with coumarin and cimetidine: long term follow-
up of patients on a phase I trial. J. Cancer Res. Clin. Oncol. 120, 535–538.
Marzano, C., Trevisan, A., Giovagnini, L., Fregonal, D., 2002. Synthesis of a
new platinum(II) complex: anticancer activity and nephrotoxicity in vitro.
Toxicol. In Vitro 16, 413–419.
Marzo, I., Perez-Galan, P., Giraldo, P., Rubio-Felix, D., Anel, A., Naval, J.,
2001. Cladribine induces apoptosis in human leukaemia cells by caspase-
dependent and-independent pathways acting on mitochondria. Biochem. J.
359, 537–546.
Maucher, A., Kager, M., von Angerer, E., 1993. Evaluation of the anti-tumour
activity of coumarin in prostrate cancer models. J. Clin. Res. Clin. Oncol.
119, 150–154.
McCann, M., Geraghty, M., Devereux, M., O'Shea, D., Mason, J., O'Sullivan, L.,
2000. Insights into the mode of action of the anti-Candida activity of 1,10-
phenanthroline and its metal chelates. Met.-Based Drug. 7, 185–193.
Mosmann, T., 1983. Rapid colorimetric assay for cellular growth and survival:
applications to proliferation and cytotoxicity assays. J. Immunol. 65, 55–63.
Murray, R.D., Mendez, J., Brown, S.A., 1982. The Natural Coumarins:
Occurrence, Chemistry and Biochemistry. JohnWiley & Sons, London, UK,
pp. 1–12.
Nagata, S., 2000. Apoptotic DNA fragmentation. Exp. Cell Res. 256, 12–18.
Nunez, R., 2001. DNA measurement and cell cycle analysis by flow cytometry.
Curr. Issues Mol. Biol. 3, 67–70.
Pillai, S.P., Menon, S.R., Mitscher, L.A., Pillai, C.A., Shankel, D.A., 1999.
Umbelliferone analogues and their potential to inhibit benzo[a]pyrene-and
hydrogen peroxide-induced mutations. J. Nat. Prod. 62, 1358–1362.
Portsmann, T., Ternyck, T., Aveameas, S., 1985. Quantitation of 5-bromo-2-
deoxyuridine incorporation into an enzyme immunoassay for the assessment
of the lymphoid proliferative response. J. Immunol. Methods 82, 169–179.
Samuni, A., Chevion, M., Czapski, G., 1981. Unusual copper-induced
sensitisation of the biological damage due to superoxide radicals. J. Biol.
Chem. 256, 12632–12635.
Sharma, S., Stutzman, D., Kellof, J.G., Steele, V.E., 1994. Screening of potential
chemopreventive agents using biochemical markers of carcinogenesis.
Cancer Res. 54, 5848–5855.
Susin, A., Lorenzo, H.K., Zamzami, N., Marzo, I., Snow, B.E., Brothers, G.M.,
Mangion, J., Jacotot, E., Costantini, P., Loeffler,M., Larochette, N., Goodlett,
D.R., Aebersold, R., Siderovski, D.P., Penninger, J.M., Kroemer, G., 1999.
Molecular characterization of mitochondrial apoptosis-inducing factor.
Nature 397, 441–446.
Tao, Z.F., Lin, N.H., 2006. Chk1 inhibitors for novel cancer treatment. Anti-
Cancer Med. Chem. 6, 377–388.
Tellingen, O.V., 2001. The importance of drug-transporting P-glycoproteins in
toxicology. Toxicol. Lett. 120, 31–41.
Tsang, S.Y., Tam, S.C., Bremner, L., Burkitt, M.J., 1996. Copper-1,10-
phenanthroline induces internucleosomal DNA fragmentation in HepG2
cells, resulting from direct oxidation by the hydroxyl radical. Biochem. J.
317, 13–16.
Verhaegh, G.W., Richard, M.J., Hainaut, P., 1997. Regulation of p53 by metal
ions and by antioxidants: dithiocarbamate down-regulates p53 DNA-
binding activity by increasing the intracellular levels of copper. Mol. Cell.
Biol. 17, 5699–5706.
Wijker, C.A., Lafleur, M.V., 1999. The presence of traces of iron and copper ions
during γ-irradiation does not result in clear mutational hot spots in the lac1
gene. Mutat. Res. 429, 27–35.
Yang, S.H., Chein, C.M., Lu, M.C., Hu, X.W., Lin, S.R., 2006. Up-regulation of
Bax and endonuclease G, and down-modulation of Bcl-XL involved in
cardiotoxin III-induced apoptosis in K562 cells. Exp. Mol. Med. 38 (4),
435–444.
Zhou, H., Lui, Y., Zhen, C., Gong, J., Liang, Y., Wang, C., Zou, C., 2002.
Microcalorimetric studies of the synergistic effects of copper-1,10-
phenanthroline combined with hyperthermia on a liver hepatoma cell line
Bel-7402. Therm. Acta 397, 87–95.
28 B. Thati et al. / European Journal of Pharmacology 569 (2007) 16–28
